MedPath

TC BioPharm Expands ACHIEVE AML Trial with New Site at Guys and St. Thomas Hospital

  • TC BioPharm has opened a new clinical trial site at Guys and St. Thomas Hospital in London to accelerate enrollment in the ACHIEVE study.
  • The ACHIEVE trial is a Phase II study evaluating TCB008, an allogeneic gamma-delta T cell therapy, for acute myeloid leukemia (AML) and MDS/AML patients.
  • Dr. Hugues de Lavallade, a hematologist with expertise in myeloid disorders, will serve as the Principal Investigator at the new site.
  • TC BioPharm anticipates data from the ACHIEVE clinical trial in the first half of 2025, with strong enrollment progress reported.
TC BioPharm (Holdings) PLC has announced the opening of a new clinical trial site at Guys and St. Thomas Hospital in London for the ACHIEVE UK trial. This Phase II study is evaluating the efficacy of TCB008, an allogeneic gamma-delta T cell therapy, in patients with acute myeloid leukemia (AML) or MDS/AML who have relapsed or refractory disease. The addition of this site aims to expedite the trial's progression and data readout.

New Site and Principal Investigator

Guys and St. Thomas Hospital, a leading London-based institution, brings extensive experience in cell therapy and oncology trials to the ACHIEVE study. Dr. Hugues de Lavallade, a consultant hematologist specializing in myeloid disorders, will serve as the Principal Investigator. His expertise in treating AML patients with measurable residual disease is expected to significantly contribute to the trial's success.

ACHIEVE Trial Design and Objectives

The ACHIEVE UK clinical trial is an open-label, Phase II study designed to assess the effectiveness of TCB008 in AML and MDS/AML patients with refractory or relapsed disease. TCB008 is TC BioPharm's allogeneic gamma-delta T cell therapy, which harnesses the unique properties of gamma-delta T cells to target and eliminate cancer cells while sparing healthy tissue. The trial aims to provide an alternative treatment option for seriously ill AML patients.

Progress and Anticipated Data

According to Alison Bracchi, Executive Vice President of Clinical at TC BioPharm, the ACHIEVE clinical trial has shown positive progress since the dose increase earlier this year, with strong enrollment and remains on schedule for data in the first half of 2025. The company is partnering with several centers of excellence to advance the trial and offer new hope to AML patients.

About TCB008

TCB008 is based on gamma-delta T cells, which are naturally occurring immune cells that can differentiate between healthy and diseased tissue. TC BioPharm is focused on developing these therapies for cancer treatment, with human efficacy data already demonstrated in acute myeloid leukemia.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Duvakitug Shows Promise in Phase 2 Ulcerative Colitis Trial with 50% Symptom Resolution Rate

A Phase 2 trial of duvakitug, jointly developed by Teva and Sanofi, has demonstrated significant efficacy in treating ulcerative colitis. The experimental antibody drug achieved symptom resolution in approximately 50% of patients receiving high doses after 14 weeks, compared to 20% in the placebo group.

Tharimmune's TH104 Advances to Phase 2 for Pruritus in Primary Biliary Cholangitis

Tharimmune plans to initiate a Phase 2 clinical trial in 2025 to evaluate TH104 for moderate-to-severe pruritus associated with primary biliary cholangitis (PBC).

Tourmaline Bio Advances Pacibekitug Program with Expanded Cardiovascular Focus

Tourmaline Bio's Phase 2 TRANQUILITY trial, assessing pacibekitug in chronic kidney disease patients with elevated C-reactive protein, has exceeded its enrollment target, with topline data expected in Q2 2025.

Theralase Expands Bladder Cancer Clinical Trial with New Sites and Promising Phase II Data

Theralase has launched new clinical study sites in the U.S. and Canada for its Phase II trial of Ruvidar™ in BCG-unresponsive NMIBC.

TC BioPharm's TCB008 Shows Promise in Phase 2b ACHIEVE Trial for Acute Myeloid Leukemia

TC BioPharm's ACHIEVE Phase 2b trial evaluates TCB008 for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS/AML).

Arch Biopartners Doses First Patient in Phase II Trial for Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners has dosed the first patient in Canada for its Phase II trial evaluating LSALT peptide for preventing cardiac surgery-associated acute kidney injury (CS-AKI).

UK Dementia Trials Accelerator Aims to Radically Increase Clinical Trial Participation

The Dementia Trials Accelerator will receive £20m in government funding to significantly increase UK participation in dementia clinical trials.

CRUK Receives $225 Million Investment; New CAR-T Cell Facility; Promising Gene Therapy for Parkinson's

Cancer Research UK (CRUK) has received a US$225 million investment to enhance cancer research and treatment, focusing on personalized medicine and early detection.

TC BioPharm to Explore Gamma Delta T-Cell Therapy TCB008 for Mpox Treatment

TC BioPharm is initiating preclinical studies for TCB008, an unmodified cell therapy, to treat Mpox, leveraging the role of gamma delta T-cells in viral infections.

£400M Investment to Establish Clinical Trial Hubs Across the UK

A £400 million public-private investment will establish up to 18 new clinical trial hubs across the UK to accelerate the development of new medicines.

Reference News

[1]
TCBP Announces Site Opening of Guys and St. Thomas Hospital - PR Newswire
prnewswire.com · Sep 25, 2024

TC BioPharm opens new site at Guys and St. Thomas Hospital in London for ACHIEVE UK Trial, aiming to expedite enrollment...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy